HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK And Pfizer Start Consumer JV For Different Reasons, Aim For Similar Goals

Executive Summary

Big pharmas' agreement could put consumer health where Pfizer wants, entirely in its rear-view mirror, and points GSK toward what it wants, more research and development funding freed up for the pharmaceutical ingredient operations that are its chief revenue drivers. All-equity deal, giving GSK 68% control and expected to close in 2019 second half, also likely will boost investors' confidence in the firms as both have been dogged by pressure to sell, spin-off or otherwise divest their consumer businesses.

You may also be interested in...



No More ‘Major’ Deals For GSK Consumer Before IPO – CEO Walmsley

GSK's CEO Emma Walmsley has effectively ruled out further big deals at its Consumer Healthcare unit before the business is separated from its parent through an IPO. 

GSK And Pfizer Assemble Consumer Healthcare Leadership Team As JV Closes

Under Brian McNamara’s leadership, GSK Consumer Healthcare has begun to assemble a management team that combines talent from both GSK and Pfizer.

GSK And Pfizer Agree To Divest ThermaCare To Win EU Approval For JV

GSK and Pfizer must find a buyer for the global rights to the ThermaCare pain relief brand to receive European Commission approval for their proposed joint venture.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS139941

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel